Chronic myeloid leukemia (CML), while traditionally a disease of the elderly, has recently risen in incidence among younger patients. Hence, fertility concerns have emerged considering the disease process and treatments, especially with the current scarce and conflicting recommendations. This review explores the impact of CML treatments including the first-line tyrosine kinase inhibitors (TKIs) and other treatments on male fertility in chronic myeloid leukemia (CML) patients. The aim of this review was to compile the available evidence on male fertility to ultimately tailor treatment plans for male CML patients for whom fertility and future chances for conception pose a concern. The data available on the conventional and newer TKIs to address fertility concerns were reviewed, particularly the potential long- and short-term effects. Also, the possible side effects on subsequent generations were a crucial focus point of this review to reach a more comprehensive CML management approach. We found and compared the evidence on TKIs approved to treat CML. We also reported the effects of hydroxyurea, interferon, and transplantation, which are considered second-line treatments. Our findings suggest that these drugs might have an undiscovered effect on fertility. More research with larger sample sizes and longer follow-up periods is essential to solidify our understanding of these effects.
慢性粒细胞白血病（CML）虽传统上被视为老年性疾病，但近年来在年轻患者中的发病率有所上升。因此，考虑到疾病进程及治疗方案，尤其是当前相关建议稀缺且存在矛盾，生育力保护问题日益凸显。本综述探讨了CML治疗手段，包括一线酪氨酸激酶抑制剂（TKIs）及其他疗法对慢性粒细胞白血病男性患者生育能力的影响。本文旨在整合现有关于男性生育力的证据，最终为关注生育能力及未来生育机会的男性CML患者制定个体化治疗方案。我们系统回顾了针对生育问题的传统及新型TKIs相关数据，特别关注其潜在长期与短期影响。同时，本文重点探讨了治疗对后代可能产生的副作用，以构建更全面的CML管理策略。我们收集并比较了已获批治疗CML的TKIs证据，同时报告了羟基脲、干扰素及移植等二线治疗方案的影响。研究发现提示这些药物可能对生育能力存在尚未明确的影响。未来需要通过更大样本量和更长随访期的研究来深化对这些影响的理解。
肿瘤(癌症)患者之家